Abstract
Success of immuno-oncology therapies depends on choosing patient populations likely to benefit. Current predictive biomarkers are unable to accurately identify subsets of patients that benefit from these therapies. Liquid biopsy analyses of circulating cell free tumor DNA (ctDNA) have shown promise in capturing tumor burden dynamics. Our pilot analyses provided proof of concept for the value of ctDNA in rapidly and accurately identifying patients that do not respond, and in monitoring the evolution of resistance to immune checkpoint blockade1.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
